Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (495)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04523688 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma(Combi G-Vax) | recruiting | Phase 2 | 28 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05909618 | Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases(14) | recruiting | Phase 2 | 33 | Sheba Medical CenterOTHER_GOV |
| 1 |
| Jul 22, 2025 |
| clinicaltrials |
| NCT07047066 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma | not yet recruiting | Phase 2 | 30 | Tongji HospitalOTHER | 0 | Jul 2, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT02780024 | Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM | active not recruiting | Phase 2 | 50 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04765098 | Tamoxifen Versus Etoposide After First Recurrence in GBM Patients | recruiting | Phase 2 | 60 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04121455 | Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients(GLORIA) | active not recruiting | Phase 1 / Phase 2 | 117 | TME Pharma AGINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT04019262 | Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 2 | John FlickingerOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06013618 | Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma | recruiting | Phase 2 | 120 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07014943 | High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 34 | Sichuan UniversityOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT01777919 | Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform(GLIODIS) | not yet recruiting | Phase 2 | 32 | Olympion Medical CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT03503864 | Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma | active not recruiting | Phase 2 | 80 | Yang LiOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06809517 | Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis | recruiting | Phase 1 / Phase 2 | 34 | Guangzhou Medical UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT03673787 | A Trial of Ipatasertib in Combination With Atezolizumab(IceCAP) | active not recruiting | Phase 1 / Phase 2 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06971406 | High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis(FLAME-1) | not yet recruiting | Phase 2 | 100 | Qiming WangOTHER_GOV | 0 | May 14, 2025 | clinicaltrials |
| NCT02378428 | MIBG Therapy for Patients With MIBG Avid Tumors(MIBG) | active not recruiting | Phase 2 | 65 | Nationwide Children's HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06598787 | A Study of BL-B01D1 in Patients With Recurrent Glioblastoma | recruiting | Phase 2 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT05664243 | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 4 | In8bio Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06948994 | A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma | not yet recruiting | Phase 1 / Phase 2 | 15 | Guangzhou Women and Children's Medical CenterOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT04737889 | Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 23, 2025 | clinicaltrials |
| NCT05209620 | Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma | recruiting | Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06936046 | Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression | recruiting | Phase 2 | 200 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06933394 | Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma | recruiting | Phase 2 | 92 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04250064 | A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma(LoBULarDIPG) | recruiting | Phase 2 | 40 | Tata Memorial CentreOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06016452 | A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma(CHROME) | recruiting | Phase 2 | 118 | Tata Memorial CentreOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06690216 | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors(PD-L1-PET) | enrolling by invitation | Phase 1 / Phase 2 | 100 | Man HuOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06901817 | A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases | recruiting | Phase 2 | 97 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06901999 | Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients | not yet recruiting | Phase 2 | 23 | Ruijin HospitalOTHER | 0 | Mar 30, 2025 | clinicaltrials |
| NCT06876688 | Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma | recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06861218 | Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases | not yet recruiting | Phase 2 | 42 | Zhejiang Cancer HospitalOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03452579 | Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM | active not recruiting | Phase 2 | 90 | David PeereboomOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06853080 | Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid Tumors | active not recruiting | Phase 2 | 6 | Taipei Medical UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06836505 | Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. | recruiting | Phase 1 / Phase 2 | 10 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04590664 | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | recruiting | Phase 1 / Phase 2 | 24 | Emory UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04881032 | AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma(NANO-GBM) | active not recruiting | Phase 1 / Phase 2 | 66 | Centre Jean PerrinOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04903899 | 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma(LuDO-N) | recruiting | Phase 2 | 24 | Jakob StenmanOTHER | 5 | Feb 11, 2025 | clinicaltrials |
| NCT01868490 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells | enrolling by invitation | Phase 1 / Phase 2 | 20 | Siriraj HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03373097 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT06710249 | Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema(AFBTEdema) | recruiting | Phase 2 | 20 | Peter SiesjöOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06780592 | Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery | not yet recruiting | Phase 2 | 60 | Huashan HospitalOTHER | 0 | Jan 22, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT04758533 | Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy(AloCELYVIR) | active not recruiting | Phase 1 / Phase 2 | 13 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06737250 | NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL(POTENTIAL-P) | recruiting | Phase 2 | 33 | NOBO MedicineINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT04195139 | Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM(NUTMEG) | active not recruiting | Phase 2 | 103 | University of SydneyOTHER | 2 | Dec 11, 2024 | clinicaltrials |
| NCT06172595 | FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma(FET PET in HGG) | recruiting | Phase 2 | 22 | Singapore General HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03395587 | Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma(GlioVax) | active not recruiting | Phase 2 | 136 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05768919 | Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | recruiting | Phase 1 / Phase 2 | 30 | SignPath Pharma, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06160206 | Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | recruiting | Phase 2 | 134 | Academic and Community Cancer Research UnitedOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT01985087 | A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 | active not recruiting | Phase 1 / Phase 2 | 18 | University of LouisvilleOTHER | 1 | Oct 31, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jul 22, 2025source: clinicaltrials